Breast Cancer: Symptoms, Causes, Treatment & Nursing Care

Carcinomas of the breast arise when epithelial cells in ducts or lobules accumulate genomic alterations that overcome normal growth checkpoints. Invasive disease breaches the basement membrane and accesses lymphatic and haematogenous routes, explaining synchronous regional nodes or distant visceral, bone, or central nervous system deposits. Ductal carcinoma in situ represents non-invasive proliferation confined to ducts; natural history varies, but untreated subsets progress to invasion over years—hence active surveillance versus excision discourse in specialty clinics.

Biologically, modern oncology stratifies breast cancer by hormone receptor signalling, HER2 oncogene dependency, proliferation indices, and emerging genomic classifiers in selected settings. That molecular label is as operational as TNM stage: it determines whether cytotoxic chemotherapy delivers incremental benefit beyond endocrine monotherapy, whether anti-HER2 antibodies or tyrosine kinase strategies apply, and whether extended endocrine layering reduces late recurrence in ER+ disease.

AJCC eighth-edition staging for breast cancer fuses anatomic extent (tumour, nodes, metastases) with biologic grade and receptor status in defined early breast cancer subsets—pathologists and tumour boards report both clinical and pathologic stage. Nurses use staging language in care plans, referral letters, and patient education packets; mismatches between imaging stage and postoperative pathology should be reconciled before consent discussions for adjuvant therapy.

↔On a small screen, swipe or scroll sideways to see the full table.

Immunohistochemistry thresholds (Allred scores, Ki-67 cut-offs) vary slightly between labs—quote the synoptic pathology report, not assumed percentages.

Many tumours present as a painless firm mass, yet lobular histology may cause subtle skin thickening or nipple inversion without a discrete lump. Breast pain alone is a weak discriminator—still document cyclical versus focal persistent pain because focal non-cyclical symptoms paired with examination change belong on radiology lists.

• Nipple discharge that is spontaneous, unilateral, and blood-stained—requires specialist breast assessment.
• Skin tethering, peau d’orange, or erythema covering a substantial quadrant—raise inflammatory carcinoma until imaging rules it out.
• Painless supraclavicular fullness or axillary nodes in a person without recent infection—suspicious for nodal metastasis.

• Progressive breathlessness with pleural effusion history in treated patients—consider pleural recurrence.
• New pathological fracture pain or neurological deficit—skeletal or leptomeningeal progression.

Risk accumulates with age, earlier menarche, nulliparity or late first full-term pregnancy, and postmenopausal obesity—adipose aromatisation elevates oestrogen signalling in ER+ disease pathways. Alcohol consumption, combined menopausal hormone therapy exceeding a few years, and thoracic radiotherapy during youth increment later incidence. Germline BRCA1/2 mutations confer high penetrance and link to ovarian cancer risk; moderate-risk genes and family clustering without identifiable mutation still warrant risk-assessment clinic models.

• Prior proliferative benign disease such as atypical hyperplasia of the breast elevates long-term invasive risk—surveillance density differs from average-risk screening.
• Type 2 diabetes correlates with obesity-associated postmenopausal risk and may complicate corticosteroid use during antiemetic regimens—glucose checks matter on admissions.
• Dense breast tissue on imaging is epidemiologically associated with higher risk and lower mammographic sensitivity—document density category for continuity when patients move regions.

Clinical assessment

Timed symptom onset, pregnancy or lactation status, prior breast surgery, hormone therapy, and family history frame triple-assessment clinics (clinical exam, imaging, pathology). Nurses record laterality, measurement of dominant mass if palpable, skin and nipple inspection, and axillary surveys—photographic documentation may support telemedicine MDT pre-referral in some systems.

Laboratory investigations

• Full blood count, renal and hepatic panels before myelosuppressive regimens; calcium and alkaline phosphatase when bone metastasis suspected.
• Tumour markers (e.g. CA 15-3) lack screening value but occasionally track advanced disease responses—never diagnose recurrence on an isolated mild bump.

Imaging

Bilateral mammography with tomosynthesis where available begins workup in most adults; ultrasound separates cystic from solid lesions and guides biopsy. Staging may incorporate contrast-enhanced breast magnetic resonance imaging when extent questions persist after standard imaging, and PET-CT in selected advanced or oligometastatic evaluations per oncologist request—not routine for every early diagnosis.

Diagnostic criteria / pathology

Core needle biopsy under image guidance yields histology and receptor panel; surgical excision provides definitive stage and lymph node status via sentinel node biopsy or axillary dissection when indicated. Oncotype DX or other multigene assays in ER+ HER2− node-negative or low-burden node-positive disease inform chemotherapy benefit—the genomics report must physically accompany MDT outcome letters.

↔On a small screen, swipe or scroll sideways to see the full table.

Locoregional

Breast-conserving surgery plus whole-breast radiotherapy achieves oncologic equipoise with mastectomy for many early-stage patients when margins and anatomy allow. Postmastectomy radiotherapy follows guideline thresholds for nodal burden and T-stage. Partial breast irradiation or intraoperative radiotherapy appears in select trial-programme patients—match education materials to the exact technique used.

Systemic therapy

• ER+ early breast cancer: extended endocrine strategies; ovarian suppression added for higher-risk premenopausal cohorts per MDT.
• HER2+ disease: perioperative anti-HER2 therapy combined with chemotherapy backbone excluding cardiotoxic stacking beyond protocol.
• Triple-negative: sequential anthracycline-taxane programs; pembrolizumab or other immunotherapy only where formulary and biomarker criteria align.

Supportive medications pair with cytotoxic schedules: ondansetron class antiemetics, bowel regimens, morphine for titratable pain under palliative or acute pain teams when prescribed, and filgrastim-type colony-stimulating factors for febrile neutropenia prophylaxis when oncology protocols mandate primary prevention.

↔On a small screen, swipe or scroll sideways to see the full table.

Treatment failure in advanced disease is seldom a single lab—it is combination symptomatic progression, imaging growth despite two lines, or declining performance status. Document objective tumour assessments verbatim from clinic letters; avoid paraphrasing RECIST conclusions.

• Lymphoedema of the ipsilateral arm or breast wall after axillary treatment.
• Radiation-induced brachial plexopathy (late) versus recurrent nodal disease—new painless weakness needs MRI.
• Thromboembolism provoked by malignancy or therapy—leg swelling on the unaffected side still requires formal exclusion.
• Bisphosphonate or receptor activator-related osteonecrosis of the jaw after dental procedures—pre-treatment dental review when foreseeable.

Population mammography between 50–69 (WHO emphasis) or programme-specific ages reduces late presentation mortality where organised screening exists. Risk-reducing surgery or chemoprevention applies to high genetic or histologic-risk cohorts after specialist consent. Alcohol reduction, weight optimisation after menopause, and exercise prescriptions are evidence-linked modifiers nurses can reinforce without substituting for oncology decision-making.

Stage I–II ER+ HER2− disease with favourable biology carries high five-year survival in treated cohorts; late recurrences beyond decade ten still occur—hence extended endocrine debates. HER2+ disease prognosis improved markedly with monoclonal therapy. Triple-negative relapse risk clusters in the first three to five years; vigilant symptom surveillance balances against unnecessary scanning.

Communication & navigation

Patients oscillate between information overload and blank shock—use teach-back after MDT visits, especially for receptor terminology. Interpreter services belong in the room for pathology-result discussions, not relayed through family alone.

Device & site stewardship

Label implanted ports with last flush and blood-return policy; teach patients to refuse peripheral blood draws on the lymphedema-risk arm when policies allow alternatives.

Documentation triggers

Record absolute neutrophil count beside temperature in chemotherapy pathways; paste exact antiemetic schedule from protocol PDFs into eMAR notes to prevent drift.

• Neutropenic sepsis pattern: fever or hypothermia with rigors after recent chemotherapy.
• Acute dyspnoea with pleuritic pain or unilateral leg swelling—pulmonary embolism until excluded.
• Thunderclap headache, new focal deficit, or seizure in metastatic or hypercoagulable states.
• Spinal pain plus new bilateral leg weakness or urinary retention—cord compression emergency.

Activate your institution’s acute oncology or emergency phone line in parallel with emergency department referral so cytotoxic drug timelines and neutropenic antibiotic policies follow national cancer standards.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of early and advanced breast cancer, the breast-MDT staging / receptor-led decision (ER, PR, HER2, Ki67), structured surgery + radiotherapy + endocrine / chemo / HER2-targeted / CDK4-6i pathway and the metastatic / neutropenic-sepsis red flags.